Bone loss after denosumab, only partial protection with zoledronate

To counter the decline in BMD after denosumab treatment is discontinued, osteoporosis patients may be transitioned from denosumab to other anti-resorptives. This report investigates whether a single infusion of zoledronate might also be an effective option to prevent bone loss after long-term denosumab treatment in postmenopausal patients is discontinued.